Get the Stockscreener App
0.1598
2.23%
-0.0016
Medicus Pharma Ltd stock is traded at $0.1598, with a volume of 1.81M.
It is down -2.23% in the last 24 hours and down -54.37% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.1614
Open:
$0.1568
24h Volume:
1.81M
Relative Volume:
0.48
Market Cap:
$10.11M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.0898
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-8.26%
1M Performance:
-54.37%
6M Performance:
-67.48%
1Y Performance:
-92.99%
1-Day Range:
$0.1535
$0.16
1-Week Range:
$0.1535
$0.2025
52-Week Range:
$0.1512
$3.05
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.16 | 10.20M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,118.73 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.38 | 641.88B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.31 | 450.61B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.00 | 357.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.50 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
FDA authorizes the next study of a skin cancer patch - Stock Titan
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - Stock Titan
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - Stock Titan
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
MDCX Should I Buy - Intellectia AI
Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
MDCX Stock Price, Quote & Chart - ChartMill
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Secures Global Rights to Pfizer’s CD228V with $12M Initial Payment and $15M Commitment - Kalkine Media
$Medicus Pharma (MDCX.US)$ - Moomoo
Medicus Pharma inks deal with Pfizer to advance clinical-stage ADC - The Pharma Letter
Pfizer, Medicus ink licensing deal worth up to $1B (PFE:NYSE) - Seeking Alpha
Medicus Pharma Signs Potential $1B Deal to License Pfizer’s Cancer Drug CD228V - Minichart
Medicus Pharma (MDCX) 10K Form and Latest SEC Filings 2026 - MarketBeat
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin - TMX Newsfile
Medicus Pharma Warrant (MDCXW) Holds Steady at $0.33 as Trading Range TightensRVOL Breakout - vinanet.vn
Medicus Pharma Ltd. Warrant (MDCXW) Holds at $0.33 as Tight Trading Range PersistsVolume Gap - siam.in
Medicus (MDCX) Update: Slides 0.15% to $0.27 in the Latest Reading; Range Check - vinanet.vn
Medicus (MDCXW) Session: Ends a Quiet Session at $0.33 for the Current Session; Range Check: the Current Price Sits Inside the Supplied Technical Range in the Available RecordStock News - vinanet.vn
Medicus (MDCXW) Shares: Records a Muted Move to $0.33 in the Latest Session; Price Setup: Price Remains Between $0.31 Support and $0.35 Resistance in the Current UpdateCall Spread Alert - vinanet.vn
Medicus (MDCX) Quarterly Figures: The EPS Result Is Below Expectation in the Available Record; The Market Price Advances 1.15%Earnings Call Highlights - vinanet.vn
A. G. P. Maintains Medicus Pharma(MDCX.US) With Buy Rating, Cuts Target Price to $0.9 - Moomoo
Medicus Pharma on Bloomberg World - Coldwater Daily Reporter
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - dailyrecord.com
Top Medicus Pharma (MDCXW) Competitors 2026 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Market movers: Cisco, Cerebras, Medicus Pharma, Ideal Power... - Proactive financial news
Medicus Pharma advances clinical programs and r... - Pluang
Medicus Pharma advances pipeline during Q2 with key milestones - Yahoo Finance
Medicus Pharma Q2 loss widens to $11.7M, misses EPS estimate - scanx.trade
Medicus Pharma Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Corsicana Daily Sun
Medicus Pharma Ltd. Q2 2026: Net loss $(11.62M), EPS $(0.21) — 10-Q Summary - TradingView
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):